AACR Project GENIE®
AACR Project GENIE® is an international, open-source pancancer registry of real-world clinico-genomic data that catalyzes discovery, informs regulatory strategy, and powers precision oncology.
Learn More
AACR Project GENIE® is an international, open-source pancancer registry of real-world clinico-genomic data that catalyzes discovery, informs regulatory strategy, and powers precision oncology.
Learn More
Cancer is not a single disease, but rather a collection of diseases all characterized by the uncontrolled proliferation of cells.
Learn MoreInvesting in Innovation: The AACR grants program sparks innovation in basic, translational, and clinical research by providing critical support to promising investigators at all career levels.
Read MoreChildhood acute lymphoblastic leukemia (ALL) is the most common type of pediatric cancer. September is Childhood Cancer Awareness Month.
Learn MoreResearchers are shedding light on the multifaceted ways that extrachromosomal DNA impacts cancer development and resistance to targeted therapies.
Learn MoreRead about recent U.S. Food and Drug Administration approvals of products for cancer prevention, diagnosis, and treatment.
Learn MoreWhether honoring a special person or a special day, a donation to the American Association for Cancer Research has a lasting impact.
Donate NowThe Call for Abstracts for the AACR Annual Meeting 2027 (April 2-7) is now available. Abstract submission will open in late September.
Abstract Deadline: November 10
The AACR Cancer Progress Report 2026 highlights the remarkable progress against cancers driven by discoveries across basic, translational, clinical, and population science.
Learn MoreThe AACR and its more than 65,000 members worldwide are advancing a scientifically bold agenda against the collection of diseases we call cancer.
Learn MoreThe AACR Cancer Disparities Progress Report 2026 provides a comprehensive overview of the latest research on cancer disparities and calls for policies to reduce disparities and achieve cancer health equity.
Learn Morepercent decrease of the overall age-adjusted cancer death rate in the U.S. from 1991 to 2024
Learn Moretherapeutics were approved for new or expanded uses by the FDA from July 1, 2025, to June 30, 2026
Learn Moremillion cancer survivors in the U.S. are living with, through, and beyond their disease thanks to research
Learn MoreYour donation to the American Association for Cancer Research helps our more than 65,000 members worldwide drive progress against cancer.
Donate Now
